"epidermal growth factor receptors" trang 7 - tải miễn phí từ tailieunhanh
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    86    0
Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
9    96    0
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
12    46    0
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer
19    91    0
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
15    87    0
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
9    81    1
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study
11    41    0
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
4    37    0
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
5    51    1
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
10    54    1
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
6    65    1
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
10    54    1
Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series

Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series
9    73    1
The association between smoking and breast cancer characteristics and outcome

The association between smoking and breast cancer characteristics and outcome
8    50    1
EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma

EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma
9    55    1
Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand
12    75    1
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
6    54    1
Effect of neoadjuvant therapy on breast cancer biomarker profile

Effect of neoadjuvant therapy on breast cancer biomarker profile
9    64    1
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    87    1